Sustainable chromatographic quantitation of multi-antihypertensive medications: application on diverse combinations containing hydrochlorothiazide along with LC–MS/MS profiling of potential impurities: greenness and whiteness evaluation

Table 5 Determination of the studied drugs in pharmaceutical dosage forms by the proposed HPLC–DAD method and application of standard addition technique

Pharmaceutical Formulation	CT			DSA
Pharmaceutical Formulation	Found (ng/mL)	Standard added ^a (ng/mL)	%R of standard added ^b	Found (ng/mL)	Standard added ^a (ng/mL)	%R of standard added ^b
Exforge HCT^®	1.07	25.0 (0.05%)	98.61	0.08	25.0 (0.05%)	101.01
Tablets		50.0 (0.1%)	101.04		50.0 (0.1%)	100.02
(Labeled to contain HCT 25.0 mg, VAL 160.0 mg and AML 10.0 mg)		100.0 (0.2%)	99.83		100.0 (0.2%)	100.20
B.N. (A518682)		Mean ± SD	99.83 ± 1.21		Mean ± SD	100.41 ± 0.53
Atenoretic^®	0.64	25.0 (0.05%)	100.94	1.47	25.0 (0.05%)	100.37
capsules		50.0 (0.1%)	99.30		50.0 (0.1%)	100.17
(Labeled to contain HCT 25.0 mg, ATN 50.0 mg and AMI 2.5 mg)		100.0 (0.2%)	100.12		100.0 (0.2%)	100.08
B.N. (71047)		Mean ± SD	100.12 ± 0.82		Mean ± SD	100.21 ± 0.15
Atacand Plus®	1.03	25.0 (0.05%)	101.56	0.05	25.0 (0.05%)	99.88
Tablets		50.0 (0.1%)	98.83		50.0 (0.1%)	100.10
(Labeled to contain HCT 12.5 mg and CAN 16.0)		100.0 (0.2%)	100.19		100.0 (0.2%)	99.99
B.N. (19015)		Mean ± SD	100.19 ± 1.36		Mean ± SD	99.99 ± 0.11

ISSN: 2661-801X